CanSino’s inhaled tuberculosis vaccine approved for clinical trials in Indonesia
May 19, 2025
Source: drugdu
99
May 15, CanSino(688185/06185) announced that the company's inhaled tuberculosis vaccine (adenovirus type 5 vector) has recently obtained clinical trial approval from the Indonesian Food and Drug Administration.
The development of this vaccine aims to solve the problem of BCG's weakening protection over time and provide more effective immune protection. According to the World Health Organization, there will be 10.8 million new tuberculosis patients worldwide in 2023, showing the continued threat of tuberculosis, especially in Southeast Asia and Africa. This Phase I clinical trial will explore the safety and immunogenicity of the vaccine in adults aged 18-49.
In the first quarter of 2025, CanSino Biologics achieved revenue of 137 million yuan and a net profit attributable to shareholders of the parent company of -11.55 million yuan.
https://finance.eastmoney.com/a/202505153405639359.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted July 10, 2025
- Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development July 10, 2025
- Small nucleic acid therapy challenges GLP-1 giants July 10, 2025
- Baili Tianheng BL-B01D1 Update Progress July 10, 2025
- FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema July 10, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
